- Research Article
- Open Access
Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
Health & Justice volume 10, Article number: 36 (2022)
Jails are optimal settings in which to screen individuals for opioid use disorders (OUD) and provide needed services, especially medications for OUD (MOUD). This study sought to assess the availability of OUD “best practices” in jails located in counties heavily impacted by opioid overdose in the U.S. and their related training and resource needs. Counties were selected for study inclusion using two indicators of OUD severity: the absolute number and population rate of opioid overdose deaths. Structured interviews were completed with representatives from 185/244 (76%) of targeted counties and 185/250 (74%) of targeted jails in these counties. Ten OUD best practices were identified based on current treatment and practice guidelines. These include: screening for OUD; clinical assessment; medically managed withdrawal; MOUD administration; MOUD for pregnant people; counseling and wrap-around services; collaboration with community providers; assistance with Medicaid/insurance; re-entry services; and overdose prevention. Descriptive analyses examined the provision of any services and average percentage of services endorsed within best-practice categories, association of best-practice availability with community and jail characteristics, and related needs for training and resources.
Over 70% of jail respondents indicated that some aspects of each of the ten OUD best practices were available within their jails, ranging from 71% using clinical assessment to 96% providing overdose prevention. However, there was considerable variability in the average percentage of items endorsed within each best-practice category, ranging from 38% of items regarding re-entry services to 88% of items regarding medically managed withdrawal. Availability of OUD best practices in jails also varied by community and jail characteristics. Jails reported the highest needs for funding for medication and clinical staff.
Policies are needed to address the identified gaps in availability of OUD best practices within jails. Training, technical assistance, and funding are needed to improve clinical capacity of jails to administer MOUD and to ensure continuity of care from jail to community, which are essential to reducing the risk of opioid-related overdose following release.
It is widely recognized that individuals with opioid use disorders (OUD) come into frequent contact with the criminal justice system (Chen et al., 2022; Winkelman et al., 2018), making the interface between these individuals and jails a unique opportunity to intervene and change the trajectories of both OUD and criminal justice system involvement. A recent study of one county found that approximately one fifth of all overdose deaths occurred among individuals who had been incarcerated in the county jail within the prior 2 years, with each booking increasing the risk of fatal overdose by about 20% (Victor et al., 2022). Moreover, the rates of fatal and non-fatal opioid overdose have escalated in the past 20 years (Hedegaard et al., 2020) and continue to increase (Mattson et al., 2021; https://www.cdc.gov/drugoverdose/nonfatal/dashboard/index.html), making it imperative that services to address OUD are available to individuals who come into contact with carceral settings.
Given the ample evidence that individuals with OUD are at high risk of opioid-related fatality upon their release from a period of incarceration (Binswanger et al., 2007; Binswanger et al., 2013; Merrall et al., 2010), many local jurisdictions have recognized the need to address the treatment of individuals with OUD while in their custody. Prominent professional organizations have also recently released policy reports and toolkits to promote the implementation of MOUD and Naloxone within jails and post-release (see: GAINS Center for Behavioral Health and Justice Transformation & Substance Abuse and Mental Health Services Administration [SAMHSA], 2020; National Governors Association & American Correctional Association, 2021; National Sheriffs’ Association & National Commission on Correctional Health Care, 2018; Substance Abuse and Mental Health Services Administration (SAMHSA), 2019). Moreover, there have been several successful legal challenges finding that the failure to provide MOUD to individuals while incarcerated violates the Americans with Disabilities Act, is medical malpractice, and constitutes cruel and unusual punishment (American Civil Liberties Union, 2021; Brezel et al., 2020).
A growing body of research demonstrates the effectiveness of treatment with MOUD for justice-involved populations (Moore et al., 2019) as it relates to reducing the risks of recidivism (Evans et al., 2019) and opioid-related relapse, overdose, and mortality (Evans et al., 2022; Lee et al., 2016). In addition, treatment with MOUD while detained or incarcerated is associated with greater likelihood of continued treatment following discharge (Hass et al., 2021; McKenzie et al., 2012; Sharma et al., 2016). Yet jails face numerous barriers to providing services to address OUD. These include stigma regarding people with OUD and OUD treatment. Negative attitudes about people with OUD among the general population may inhibit expansion of and funding for MOUD treatment, particularly for justice-involved populations. A national population survey of beliefs about opioid addiction found that stigma associated with OUD was positively associated with support for discriminatory actions against people with OUD in areas such as education, health care, employment, and housing; it was negatively associated with support for expanding insurance coverage for treatment of OUD, expanding access to Naloxone, and increasing government funding for OUD treatment (Adams et al., 2021; Taylor et al., 2021).
Among correctional administrators and staff, use of MOUD is often considered inferior to abstinence-based treatments and viewed negatively as a “substitute” addiction, leading to policies that restrict its use (Streisel, 2018; Wakeman & Rich, 2018). Moreover, many individuals with OUD have had prior aversive experiences in jails, such as being forced to undergo withdrawal if currently on MOUD or receiving inadequate medication dosing, leading to negative beliefs about use of MOUD (Fu et al., 2013; Rich et al., 2015). Administrative barriers also limit MOUD availability in jails, including those related to licensing and regulations on dispensing of medications; other barriers are concerns about diversion and limited space and clinical capacity (Friedmann et al., 2012; Grella et al., 2020). A recent study of MOUD implementation in four prison and jail systems in the Northeast underscored barriers to implementing MOUD stemming from a lack of funding and clinical space; negative perceptions related to MOUD; frequent exclusions or discontinuation of treatment based on patient factors, movement or transfer of individuals; and challenges to sustaining care coordination at the time of release (Ferguson et al., 2019).
Even when MOUD and related services are reported as being available within jails, access to and actual provision of these medications within jails are often severely restricted in terms of who can receive it and when. For example, in some jails where MOUD has been nominally available, its use has often been restricted to pregnant women, and usually discontinued at the end of the pregnancy (Fiscella et al., 2004; Sufrin et al., 2020). Not only is access to MOUD limited to specific subgroups of individuals, access can be limited in terms of when someone can actually receive it, for example, only upon release. One study using administrative records found that slightly less than one third of individuals who were screened as having OUD received any MOUD while incarcerated (Ray et al., 2022). This is a good example of jails reporting that MOUD is available but not disclosing that its actual availability is significantly restricted, leading to inaccurate characterizations of the extent of MOUD accessibility.
Although prior studies have examined the availability of MOUD in jails as well as the barriers to its delivery, much less is known about the incorporation of best practices for addressing OUD among individuals in jail and the training, resource, and technical assistance needs to expanding the provision of best practices to this population. This study uses the framework of the OUD service cascade, which has been used to evaluate the sequential process by which individuals are screened and engage in treatment for OUD, particularly MOUD, and to identify gaps in service delivery (Scott et al., 2020; Socías et al., 2018; Williams et al., 2017; Williams et al., 2018). This study was guided by the following research questions:
To what extent have OUD best practices been incorporated in jails that are located in areas that have been most heavily impacted by opioid-related overdose?
Does availability of OUD best practices vary across characteristics of the jails and communities in which they are located?
What types of training, technical assistance, and resources are needed to expand the availability of best practices for OUD in jails?
Given the lack of county-level prevalence data on OUD, the research team used opioid overdose deaths as a proxy for the opioid epidemic severity in counties. Opioid overdose deaths are not evenly distributed across the general population or counties, with the vast majority of overdose-related mortality concentrated in a sub-set of counties. Thus a representative sample of jails would have large standard errors and the average would primarily reflect the practices of jails in counties with relatively low rates of opioid-related mortality – and therefore may have less imperative or ability to respond. A second issue was that the epidemic looks very different in urban and rural areas (Altekruse et al., 2020; Haffajee et al., 2019; Hollingsworth et al., 2017; Monnat, 2018, 2019; Pear & Monnat, 2019; Rigg et al., 2018). Therefore, this study focuses on the counties with the highest concentrations of opioid-overdose mortality. In consultation with senior scientists from the Bureau of Justice Statistics and a nationally recognized sampling statistician, two strategies were used to identify a census of counties that were highly impacted by opioid-related deaths: 1) the subset of counties that accounted for half of all opioid-related deaths, and 2) those counties that had a significantly higher rate of opioid-related deaths per 100,000 people than the national average.
Using data from the Centers for Disease Control and Prevention Multiple Causes of Death, the research team identified 48,476 opioid-overdose deaths in the U.S. during 2017. This represented the most recent annual data available just prior to initiation of the study, comprising surveys of state prison systems (see Scott, Dennis, Grella, Mischel, & Carnevale, 2021) and jails (present study). Supplement A contains two maps showing, by county, the number of opioid-overdose deaths and crude rates of opioid overdose death in 2017. While there is overlap in the counties, the two maps show distinct patterns: high numbers of opioid-overdose deaths predominate in counties with large urban populations, whereas high rates of opioid-related deaths occur in more rural counties. Those meeting both criteria (n = 56) tend to be more mid-size counties. Taken together, the two maps show how the opioid epidemic is concentrated in a subset of all U.S. counties and varies by region.
To derive the study sample of counties, we identified the top 97 counties that accounted for 50% of all opioid overdose deaths nationally. Second, we identified an additional 147 counties that had crude rates of opioid-related overdose deaths per 100,000 people with their 95% confidence interval completely above that for the U.S. rate (14.5 to 14.8). The combined census of 244 counties accounted for 66% of all opioid-related deaths in the U.S. and had significantly higher crude rates of opioid-related overdose deaths per 100,000 people than the U.S. overall (20.3 vs. 14.7). These counties were diverse in both total population and jail census. In terms of population, 14% of the counties had 1 million or more people, 36% had 250,000 to 999,999 people, and 50% had fewer than 250,000 people. In terms of the number of people confined to jail, 11% of the counties had jails with 5000 or more people confined, 41% had 1000 to 4999 people confined, and 48% had less than 1000 people confined.
To identify the jails within each of the above counties, the research team used information from the Bureau of Justice Statistics and National Institute of Corrections. Additional information was obtained from internet searches of county websites, searching for “jail,” “detention center,” “sheriff’s office,” or “sheriff’s department” in each county to obtain the name and address of the sampled jail and phone number and/or email address for an office or person to use as an initial contact. Consistent with earlier studies (Foudray et al., 2021), these jails included public and privately run facilities, other confinement facilities (e.g., detention centers), and facilities with individuals that were both pre- and post-adjudication. While most counties had only one primary jail under a Sheriff or county administrator, the list included some large city jails, regional jails serving more than one county, and large urban jails that held people from other nearby jurisdictions. We excluded other community supervision programs (e.g., diversion, electronic monitoring, house arrest, probation, parole) and temporary holding facilities only used by courts or police for 72 hours or less. We also excluded counties from states with a single integrated prison-jail system that were included in a prior report (Scott, Dennis, Grella, Mischel, & Carnevale, 2021).
The interview was structured as a survey to assess availability and accessibility of: 1) opioid withdrawal management; 2) screening and assessment to identify opioid use problems; 3) MOUD provision, including eligibility, reasons for use, and restrictions on use; and 4) re-entry planning and services, consistent with other criminal justice-focused service cascade models (Belenko et al., 2017; Dennis et al., 2019; Ray et al., 2022). Given the high risk of opioid overdose during incarceration and following release, we included a section on overdose prevention services, based on recommendations of the National Commission on Correctional Health Care (2022). Lastly, respondents were asked about their needs for training, technical assistance, and resources to improve their ability to provide OUD services.
Study measures were developed through a review of previous studies of OUD-related services and treatment within both prisons and jails, as well as consultation with correctional representatives and stakeholders. Information on interview development, including the interview measures and the sources consulted to derive the interview content, are contained in Supplement B. To aid in evaluating the quality of the responses when the information was not available, the interview’s survey format allowed respondents to indicate whether their response was estimated, or whether the information was not accessible to them or was not collected. Most questions were closed-ended, although “other” responses and open-ended questions were included where relevant. These responses were keyed verbatim.
To help understand the patterns of OUD service delivery in jails, additional county-level geocoded data were linked to the interview data to examine community characteristics, such as gender and racial and ethnic demographics, population rate of incarceration, urbanicity, level of poverty in the county in which the jail was located, and availability of MOUD providers in the county. Some of these data are represented as average percentages of population characteristics across counties and others are mean values. These data came from the Opioid Environment Policy Scan database at geodacenter.github.io/opioid-policy-scan/. This public use data set includes data from the Bureau of Justice Statistics, Centers for Disease Control and Prevention, the Current Population Survey, and SAMHSA (Kolak et al., 2021).
The study team collaborated with state and local sheriff’s associations and other key stakeholders in the targeted counties to identify appropriate respondents for the interview. An interview coach was assigned to each jail contact to provide a study overview, answer questions, and facilitate the interview process. Coaches were BA- or MA-level research assistants with prior experience working on criminal justice-related studies/projects and were extensively trained through videos, webinars, in-person training and review of digital recordings. All interviews were attempted between December 2019 to February 2021, and the interview focused on the most recent 12-month period. For all jails, this 12-month referent period occurred prior to onset of the COVID-19 pandemic.
The structured interview protocols were in a “survey” format. Typically, no individual could answer all the questions and several required consulting other resources, such as annual reports or other administrative data. Hence, the interview process was conducted through a series of stages: a) approaching individual jails through state or other professional associations they trusted; b) providing them an overview of the study’s purpose, survey component, options for completing it, and the coaching process; c) agreeing on the best way for each individual jail to respond via interview, written response or a combination of both (95% of jails opted for a combination); at this time, administrators often designated an individual or a multidisciplinary team to complete the interview; d) answering questions during this process by their coach; e) returning the instrument via phone, email, fax, or a combination of the three; this sometimes included review of the draft answers with back and forth follow-up to clarify any inconsistencies and explore ways to fill in any missing data; and f) providing each jail with a summary report of their answers vs the answers of all jails across the country and answering any questions they had (in a few select cases, correcting an answer). Only then was the data for each jail considered final.
The interview process required four to twelve weeks to finalize and cumulative interview time ranged from 30 to 90 minutes. Depending on the range of services provided, as indicated by the respondent and availability of information requested, most interviews required input from multiple people/sources and often took place over several sittings to collect the requested information. Phone interviews were audio-recorded to ensure the accuracy of responses. All interviews were reviewed for completeness, inconsistent responses, and legibility.
Interviews were completed with representatives from 185/244 (76%) of targeted counties and 185/250 (74%) of the targeted jails in these counties, which is comparable to or higher than prior surveys conducted with correctional administrators (Taxman et al., 2007) or that use online or mail contact only (Foudray et al., 2021). Additional detail on respondent characteristics is provided in the Results section. Respondents were not compensated for their participation. The study obtained a Certificate of Confidentiality from the National Institutes of Health and was conducted under the supervision of Chestnut Health Systems’ Institutional Review Board for the Protection of Human Subjects.
Data were analyzed with IBM SPSS™ Version 27, using the frequencies and descriptive procedures, including t-tests for continuous measures and chi-square tests for categorical measures. Responses were eliminated from the analyses when data for 15% of counties on any given item were missing. This includes when it was either unavailable or not systematically collected. Where one or more counties were missing, the mean of the valid responses was reported (the equivalent of mean replacement). For some questions (e.g., type of MOUD available), there were skip outs, and the questions were asked only when applicable. These cases are clearly noted in the text and tables.
The primary unit of analysis is a “jail” at the organizational level. Although the interview included some questions that asked respondents to report characteristics and services at the individual (detainee) level, these data were often unavailable to the jail administrator or could not be easily retrieved. Because of the large amount of missing information, data from these questions at the individual-level were eliminated from analyses.
OUD best practices
To evaluate the availability of best practices to address OUD within jails, the study team reviewed treatment and practice guidelines that recommended best practices for developing, implementing, and sustaining jail-based OUD-related services (see Supplement B). Best practices were recommended by a variety of sources, including treatment protocols endorsed by SAMHSA for withdrawal management, induction and maintenance treatment with MOUD, and ongoing monitoring for the general population (2018) and specifically for criminal justice settings (2019); and guidelines and recommendations from the National Sheriffs’ Association and National Commission on Correctional Health Care (2018), and the National Governor’s Association and American Correctional Association (2021). These documents recommended best practices that were based on recommendations from expert panels, review of best practices that were not criminal justice specific (e.g., American Society of Addiction Medicine), and systematic literature reviews and other scientific literature (e.g., Grella et al., 2021). Review of these materials led to identification of ten core OUD best practice domains that were consistently addressed across these sources, following the general framework of the OUD service cascade within correctional settings. These included: 1) screening for OUD, 2) clinical assessment by qualified treatment provider, 3) medically managed withdrawal, 4) MOUD administration, 5) services for pregnant women, 6) counseling and wrap-around services, 7) collaborative relations with community MOUD providers, 8) assistance with applications for state Medicaid/insurance coverage, 9) re-entry services, and 10) overdose prevention.
Between 1 to 7 items from the interview that corresponded to each of the 10 OUD best-practice domains are listed individually in the descriptive statistics. We also calculated the average number of items endorsed across each domain. Finally, a summative score was computed for percentage of services provided across the 10 best-practice categories (possible range 0–100%, median = 67%), which was used to categorize jails into 2 groups based on a median split: Low (0–67% of items endorsed), and High (above 67%). The association of best-practice categories (Low, High) with community and jail characteristics using the geocoded data was compared using crosstabulations and chi square statistics for categorical variables and t-tests for mean values – with jail as the unit of observation and analysis.
Jail and respondent characteristics
Survey responses were obtained from 185/244 (76%) of targeted counties and 185/250 (74%) of the targeted jails in these counties. To evaluate whether there was non-response bias, we compared jails that did and did not complete the interview using geocoded data on characteristics of the jails and the communities in which they were located (tabled results in Supplement C). Respondent jails were significantly (p < .05) more likely than non-respondents to be from counties that have larger populations (Means = 575,523 vs. 517,011). Relative to jails that responded, those that did not respond were more likely to be from counties with more people living below the federal poverty line (13% vs. 15%), and to have higher population incarceration rates per 100,000 people overall (324 vs. 409) as well as specifically for females (97 vs. 129), males (555 vs. 699), and white non-Hispanics (245 vs. 317). There were no significant differences between responding and non-responding jails by census region, urbancity, population race/ethnicity, jail size, or availability of MOUD providers within the county.
Among the study sample, nearly all jails (95%) are under the auspices of the Sheriff’s office or the county. Most jails house both males and females (96%), although 4% house males only. When asked about the model of health care services provision, 72% indicate they contract out for services, 11% use direct services provision, and 16% use a hybrid or other type of model. The average number of admissions across participating jails during the 12-month reference period of 2019 was 17,232 (SD = 57,710; total = 3,187,920 admissions), although this was highly variable with a median of 6602 and a range of 545 to 636,833.
The respondents for the 185 jails included jail administrators (54%), medical/behavioral health directors (18%), health services administrators (8%), program/service directors (6%), and other administrative staff (14%). They reported an average of 5.0 years (SD = 4.9) in their current position and 16.0 years (SD = 10.8) in the corrections field. In most cases, respondents identified one (n = 101), two (n = 43), or three (n = 2) additional people who assisted in gathering needed information. These additional respondents were jail administrators (31%), health services administrators (22%), medical/behavioral health directors (15%) or providers (13%), and program/service directors (12%) who had an average of 5.1 years (SD = 5.4) in their current position and 14.2 years (SD = 10.6) in the corrections field.
Availability of OUD best practices in jails
Table 1 shows the distribution of the ten OUD best practice categories and their respective sub-items for the total sample. Over 70% of respondents indicate that provision of some aspects of each of the ten best practices are available within their jail, ranging from 71% of jails providing clinical assessment to 96% providing overdose prevention. However, there is considerably more variability in the extent to which services are provided based on average percentage of items endorsed within each category, ranging from 38% of items regarding re-entry services to 88% of items for medically managed withdrawal.
Specifically, 95% of the jails indicate the use of a protocol for OUD screening, yet only 22% utilize a standardized tool. Similarly, 96% of jails indicate they have a physician-approved protocol to address opioid withdrawal, however, fewer (81%) use an FDA-approved medication for withdrawal management. Most jails (92%) have some MOUD availability, and over 70% had each type of medication nominally “available,” however, only 20% stated they provide MOUD to anyone who is assessed with OUD. Most jails that house women have some type of MOUD available for pregnant women (85%); slightly over half (53%) have both methadone and buprenorphine available for pregnant individuals, with others providing either methadone or buprenorphine. Nearly all jails (93%) provide some type of counseling or wrap-around services along with MOUD, most frequently other non-MOUD treatment services and self-help groups or other recovery support (85% for each).
With regard to best practices at discharge, 72% of the jails indicate they engage in some collaborative activities with community MOUD providers or parole/probation to facilitate continuity of care, most often by scheduling appointments with a community MOUD provider (68%), and less often by coordinating services with parole or probation (50%). Most jails (73%) assist individuals with applying for state Medicaid or other insurance to ensure continuity of coverage, although the extent of these services is highly variable, with an average of 58% of items endorsed. Similarly, 75% of jails provide some re-entry services at discharge, including transportation at discharge (47%), written prescriptions for MOUD (18%), and other activities to facilitate linkage to MOUD (21%). Lastly, although most jails (96%) provide some type of overdose prevention services, these are mainly to provide training (93%) or Naloxone kits to staff (96%), with one third or fewer providing Naloxone education and training to individuals prior to their release or Naloxone kits at discharge.
Association of OUD best practices availability with community and jail characteristics
We examined the association of OUD best practices availability, categorized as either high or low based on a median split, with jail and community characteristics (see Table 2). There were several differences between high and low best-practices groups with regard to community population characteristics. Jails in the high best-practices group had a higher mean that the low group in terms of total population (748,391 vs. 434,857), a higher proportion of Hispanic residents (13% vs. 8%), and a lower proportion of residents living in poverty (12% vs. 14%). Characteristics of jails also differed across high and low best-practice groups. Jails in the high group had lower average annual jail admissions (3682 vs. 5739) and lower average rates of jail admission per 100,000 population overall (296 vs. 347), as well as specifically for females (86 vs. 108), males (512 vs. 591), and white, non-Hispanics (219 vs. 267). There were no differences between best-practice groups, however, in census region, urbancity, or proximity to a MOUD provider, including by type of medication.
Training and resources needed to increase OUD best practices in jails
The interview assessed the types of training/technical assistance, resources, and education needed by respondents to increase their ability to provide OUD services (see Table 3). Needs for funding were most frequently endorsed, with respondents indicating they needed additional funds for medication (81%), clinical staff (80%), diversion prevention (76%), transportation to MOUD (65%), and MOUD in the community (61%). Needs for education were endorsed across a range of both correctional and community stakeholders; these include state/local politicians (68%), probation/parole staff (67%), general community (67%), correctional staff (65%), people who are incarcerated (65%), pregnant women (61%), judges (61%), and clinical staff/physicians (60%). The most frequently endorsed need pertaining to logistical support was help to minimize diversion (64%). Addressing stigma was another prominent concern, with 69% indicating a need for help in this area.Department of CorrectionsDOC administrators
With regard to clinical capacity, respondents indicated the highest needs for medical staff (71%), training on how to match client needs with type of medication (62%), and how to switch between types of medication (60%). Needs for re-entry support were also highly ranked by respondents; 70% indicated they needed additional funding for MOUD post-release; 69% endorsed the need for same-day access to MOUD; and 69% needed help to address barriers related to regulatory, insurance or managed care limits for post-release continuation of MOUD. Other highly rated needs to facilitate re-entry included access to sober/recovery housing (69%), employment (65%), and help for individuals who were returning to communities without MOUD availability (63%).
This study provides a comprehensive picture of the availability of best practices for addressing OUD among individuals in jails located in counties that have been most heavily impacted by the opioid epidemic. Given the high number and frequency of contacts that individuals with opioid use disorders have with jails (Zeng & Minton, 2021), it is essential that best practices are available to address the treatment needs of this population. Combined, these jails had over 3 million admissions during the 12-month reference period (2019) assessed in the interview. The counties in which they are located accounted for 66% of all the opioid-overdose deaths in the U.S. and had significantly higher rates of opioid-related overdose than the national average (20.3 vs 14.7 per 100,000 people) in the sampling referent period. Prior studies have evaluated the availability of evidence-based treatment practices for individuals with drug or alcohol use disorders generally in criminal justice settings (Friedmann et al., 2007); the current study focused on best practices specifically for individuals with OUD in these jails in areas heavily impacted by the opioid epidemic.
The study found that over 70% of jails in the sample provided some aspects of each of the ten best practice categories. When examined in terms of the extent of services provided within each category, however, there was considerable variability in implementation. It is noteworthy that several of the best practice areas that were least fully implemented pertained to continuity of care, including re-entry services at release, assistance with insurance applications, MOUD for pregnant people, and collaboration with community MOUD providers. Considerable research has documented the need to enhance collaborative relationships between jails and community MOUD providers to ensure continuity of care, as well as the challenges encountered in building these cross-system relationships (Friedmann et al., 2015; Monico & Mitchell, 2016; Welsh et al., 2015). Building these collaborations may require policy directives and dedicated funding to ensure that such collaborations can be developed and sustained.
Moreover, even if adequate re-entry access to community-based MOUD treatment is readily available, individuals released from jail face numerous challenges to treatment engagement (Mitchell et al., 2021). Access to Medicaid coverage for MOUD is essential, as it has been demonstrated to increase MOUD treatment utilization among individuals involved with the criminal justice system (Khatri et al., 2021). Several strategies to promote treatment linkage and engagement at jail re-entry have been examined, including peer and patient navigation interventions, intensive case management initiated while in jail and continuing following discharge, and motivational linkage and referral interventions (Grella et al., 2022). Studies participating in the National Institute on Drug Abuse (NIDA)-sponsored Justice Community Opioid Innovation Network (JCOIN) include several randomized clinical trials examining different linkage facilitation strategies to connect individuals with community-based MOUD treatment at jail discharge (Ducharme et al., 2021; Scott, Dennis, Grella, & Watson, 2021).
There was also variability in services availability by community-level characteristics. Availability of OUD best practices in jails was more common in counties that had larger populations, a higher percentage of Hispanic residents, fewer people living below the poverty line, and lower numbers/rates of jail admissions. Although we did not find differences by region or urbancity, the sample was small and may have limited power to detect such differences. Several studies have shown regional variation in OUD services, particularly related to rural and urban differences, that impact access to community MOUD treatment providers (Singer & Kopak, 2021). Thus, different strategies may be needed in rural areas with fewer community resources as compared with highly affected urban areas that are relatively better resourced. Moreover, successful MOUD implementation in jails is typically a lengthy process that requires a sustained commitment of funding, strong leadership, effective collaboration with community treatment providers, and use of data-driven strategies for continuous monitoring and quality improvement (Ferguson et al., 2019). Study respondents indicated high levels of need to educate diverse community stakeholders about MOUD provision in jail, which is a critical component of a multi-pronged strategy. A recent legislative initiative enacted in Massachusetts that established pilot programs in 5 counties to provide MOUD to individuals while in jail and at least 30 days prior to their release, including use of all 3 approved forms of MOUD, provides one example of legislative leadership in this area (see https://malegislature.gov/Laws/SessionLaws/Acts/2018/Chapter208).
Jails reported a number of challenges affecting their ability to expand availability of OUD best practices. The majority of jails indicate that additional funds were needed to help purchase and administer MOUD-related services, hire and train more clinical staff, or to prevent diversion. Over two-thirds also reported needing help to address stigma that often serves as an obstacle to services implementation, access, and retention. Most requested help educating an array of stakeholders about OUD and MOUD, including representatives of correctional, judicial, polictical, health care, and community sectors, all of whom can help to facilitate implementation of OUD-related services in jails.
Implications for policy and practice
Given the high risks of relapse and opioid-overdose fatality following jail release (Alex et al., 2017), MOUD availability in the community, or the lack thereof, raises ethical and logistical issues for jails. Specifically, during the planning phase of this project, numerous stakeholders raised questions about the ethics of initiating MOUD with individuals while incarcerated, knowing that it was unlikely they would be able to continue their treatment upon release due to limited community access. As noted previously, community re-entry is a high-risk period for opioid relapse and overdose. Abruptly stopping treatment with MOUD is likely to bring on withdrawal and relapse to use, thus posing both ethical and safety concerns. In this study, several of the needs jail respondents identified were related to their inability to ensure continuity of MOUD treatment, which necessitates a broader, system-level approach to engage community MOUD treatment providers. This real concern has to be simultaneously addressed when pressing legislative guidance and/or in legal challenges to lack of MOUD provision related to the Americans with Disabilities Act, malpractice, or cruel and unusual punishment (Weizman et al., 2021).
The consequences of lack of MOUD availability, both during incarceration and upon release to the community, can be expressed in terms of potential opioid-related deaths that are averted when MOUD is provided to those who need it. This is illustrated in a recent simulation study using data from the National Center for Vital Statistics, which estimates that 668 lives out of every 10,000 incarcerated people nationally would be saved if all incarcerated individuals who had clinical need for MOUD had received it; additionally, 1609 lives out of every 10,000 incarcerated people would be saved if they had received MOUD both while incarcerated and after release (Macmadu et al., 2020). Achieving continuity of care across jail and community settings regarding MOUD service provision is key to addressing this public health crisis. Providing support for one but not both undermines the chances for success at mitigating the damaging effects of the continually evolving and expanding opioid epidemic (Jalal et al., 2018; Kertesz, 2017), which now accounts for more deaths in the United States than those from motor vehicle deaths, gun violence, and even exceeds deaths from human immunodeficiency virus (HIV) at the height of the 1990s HIV epidemic (Ciccarone, 2019).
As demonstrated by the wide range of needs identified by study respondents, jails need help particularly with funding to expand MOUD availability and clinical capacity; for re-entry support to ensure continuity of care, such as transportation to providers, funding for MOUD in the community, and same-day access to MOUD upon release; to address regulatory barriers; and to prevent diversion. It is noteworthy that a recent expert panel on state-level policies to improve access to OUD treatment identified automatic Medicaid enrollment for individuals leaving correctional settings as both highly implementable and effective in improving patient and population-level outcomes (Smart et al., 2022). In addition, study repondents identified MOUD-related stigma as a barrier to expansion of MOUD provision within local corrections and treatment systems and the need for education and training for stakeholders in both corrections and the local community to alleviate this barrier.
Study strengths and limitations
The study has several strengths, including: a) focusing on jails most likely to implement OUD services because of the high needs in their communities stemming opioid overdose, b) a high jail response rate (76%) despite data collection occurring largely during the COVID-19 pandemic, which entailed considerable stress for these organizations (Stephenson, 2020), and c) detailed measures of services along the OUD service cascade overall that correspond with identified OUD best practices. In terms of limitations, this is an observational study at the organizational level based on jail reports from one or more jail officials. It does not include individual-level data from administrative records; thus, we are unable to determine receipt of OUD best practices at the individual level. As noted previously, for this reason we characterize the reported “availability” of OUD best practices, but cannot determine the extent of their actual provision. In addition, due to the selection criteria, study findings may not generalize to jails in areas less impacted by the opioid epidemic or that are in transition to increasing prevalence of individuals with OUD and opioid-related overdose. Non-respondent jails also tended to be from counties that were similar to those with lower rates of best practice implementation (i.e., less population, higher poverty levels, higher rates of incarceration). Thus, although the study achieved a relatively high response rate, availability of OUD best practices in jails may be even less than suggested by the study findings if non-responding jails were less likely to implement these practices. Conversely, the higher response rate of jails in more populous counties with lower rates of jail admissions per 100,000 people should be taken into consideration. Because of their higher numbers and/or population rates of opioid overdose, these areas may have more rapidly implemented aggressive policies to address their highly visible opioid-related problems, including expansion of OUD-related services in both community and correctional settings (Barocas et al., 2018; Clarke et al., 2018; Evans et al., 2021; Rawson et al., 2019; Simpatico, 2015).
We note that jail respondents often reported that some data were not available to answer questions, particularly the more detailed questions related to the number of people receiving specific services. For example, these include: number of persons confined on (target date) by type of offense, gender, pregnancy status, age, race, ethnicity; number that received medically supervised withdrawal for OUD and that received any MOUD and specific types of MOUD; and total number of new admissions and new admissions with OUD. Since these items had large amounts of missing data, they were dropped from the analyses, precluding analyses of the extent to which services were provided to the designated population of individuals with OUD, which is a limitation of the study. Nor could we independently audit or validate responses for those who provided this information.
It is important to note that this study is also just one wave. Although about half the interviews were completed during the first 10 months of the COVID-19 pandemic, the 2019 reference period occurred completely before the pandemic started. A subsequent survey will need to examine how availability of OUD best practices in jails has been impacted by the pandemic. Many of the resources consulted to identify OUD best practices were published after the study was initiated in 2017. Fortunately, many of these issues were identified in advance by representatives of these organizations who were advising the study design and instrumentation.
Finally, the study findings provide an indication of OUD service availability in jails at one moment in time, and policies in this area are rapidly changing. Future research is needed to track changes in service availability, particularly related to changes in opioid-related mortality, which has continued to steadily increase with greater use of synthetic opioids (e.g. fentanyl and fentanyl analogs) and combined opioid and stimulant use (Ciccarone, 2021). Future studies can build on these findings to develop optimal OUD service configurations and to refine OUD best-practice categories to reflect the relative importance/necessity of specific services and their relationship with outcomes.
In sum, the study findings help to illuminate the extent to which OUD best practices have been implemented in jails that are most severely impacted by opioid overdose within their communities. It also highlights the significant need and interest from these jail in obtaining further training, technical assistance, education, and funding to expand the implementation of the OUD service cascade. Lastly, the study demonstrates the need for better coordination between jails and local communities to ensure continuity of MOUD treatment during incarceration and following release. To maximize public health and safety, policy experts, regulatory bodies, and governmental agencies need to consider the impact of the lost opportunities for reducing OUD, opioid-overdose deaths, and recidivism that result from the lack of greater MOUD availability and accessbility.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Food and Drug Administration
Global Appraisal of Individual Needs
Human immunodeficiency virus
Justice Community Opioid Innovation Network
Memorandum of understanding
Medication for opioid use disorder
National Commission on Correctional Health Care
National Institute on Drug Abuse
Opioid use disorder
Substance Abuse and Mental Health Services Administration
Statistical Package for the Social Sciences
Adams, Z., Taylor, B. G., Flanagan, E., Kwon, E., Johnson-Kwochka, A. V., Elkington, K. S., … Aalsma, M. C. (2021). Opioid use disorder stigma, discrimination, and policy attitudes in a U.S. national sample of young adults. Journal of Adolescent Health, 69(2), 321–328. https://doi.org/10.1016/j.jadohealth.2020.12.142.
Alex, B., Weiss, D. B., Kaba, F., Rosner, Z., Lee, D., Lim, S., … MacDonald, R. (2017). Death after jail release: Matching to improve care delivery. Journal of Correctional Health Care, 23(1), 83–87. https://doi.org/10.1177/1078345816685311.
Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020). Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the mortality disparities in American communities study (MDAC). PLoS One, 15(1), e0227966. https://doi.org/10.1371/journal.pone.0227966.
American Civil Liberties Union. (2021). Over-jailed and un-treated: How the failure to provide treatment for substance use in prisons and jails fuels the overdose epidemic. https://www.aclu.org/report/report-over-jailed-and-un-treated
Barocas, J. A., White, L. F., Wang, J., Walley, A. Y., LaRochelle, M. R., Bernson, D., … Linas, B. P. (2018). Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: A capture-recapture analysis. American Journal of Public Health, 108(12), 1675–1681.
Belenko, S., Knight, D., Wasserman, G. A., Dennis, M. L., Wiley, T., Taxman, F. S., … Sales, J. (2017). The juvenile justice behavioral health services cascade: A new framework for measuring unmet substance use treatment services needs among adolescent offenders. Journal of Substance Abuse Treatment, 74, 80–91. https://doi.org/10.1016/j.jsat.2016.12.012.
Binswanger, I. A., Blatchford, P. J., Mueller, S. R., & Stern, M. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. https://doi.org/10.7326/0003-4819-159-9-201311050-00005.
Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison – A high risk of death for former inmates. New England Journal of Medicine, 356, 157–165. https://doi.org/10.1056/NEJMsa064115.
Brezel, E. R., Powell, T., & Fox, A. D. (2020). An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Substance Abuse, 41(2), 150–154. https://doi.org/10.1080/08897077.2019.1695706.
Chen, Q., Sterner, G., Segel, J., & Feng, Z. (2022). Trends in opioid-related crime incidents and comparison with opioid overdose outcomes in the United States. International Journal of Drug Policy, 101, 103555. https://doi.org/10.1016/j.drugpo.2021.103555.
Ciccarone, D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. International Journal of Drug Policy, 71, 183–188. https://doi.org/10.1016/j.drugpo.2019.01.010.
Ciccarone, D. (2021). The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Current Opinion in Psychiatry, 34(4), 344–350.
Clarke, J. G., Martin, R. A., Gresko, S. A., & Rich, J. D. (2018). The first comprehensive program for opioid use disorder in a US statewide correctional system. American Journal of Public Health, 108(10), 1323–1325. https://doi.org/10.2105/AJPH.2018.304666.
Dennis, M. L., Smith, C. N., Belenko, S., Knight, D., McReynolds, L., Rowan, G., … Wiley, T. (2019). Operationalizing a behavioral health services cascade of care model: Lessons learned from a 33-site implementation in juvenile justice community supervision. Federal Probation, 83(2), 52.
Ducharme, L. J., Wiley, T. R., Mulford, C. F., Su, Z. I., & Zur, J. B. (2021). Engaging the justice system to address the opioid crisis: The justice community opioid innovation network (JCOIN). Journal of Substance Abuse Treatment, 128, 108307. https://doi.org/10.1186/2194-7899-1-5.
Evans, E. A., Stopka, T. J., Pivovarova, E., Murphy, S. M., Taxman, F. S., Ferguson, W. J., … MassJCOIN Research Group (2021). Massachusetts justice community opioid innovation network (MassJCOIN). Journal of Substance Abuse Treatment, 128, 108275. https://doi.org/10.1016/j.jsat.2021.108275.
Evans, E. A., Wilson, D., & Friedmann, P. (2022). Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 231, 109254. https://doi.org/10.1016/j.drugalcdep.2021.109254.
Evans, E. A., Zhu, Y., Yoo, C., Huang, D., & Hser, Y.-I. (2019). Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction, 114(8), 1396–1404. https://doi.org/10.1111/add.14620.
Ferguson, W. J., Johnston, J., Clarke, J. G., Koutoujian, P. J., Maurer, K., Gallagher, C., … Taxman, F. S. (2019). Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails. Health and Justice, 7, 19. https://doi.org/10.1186/s40352-019-0100-2.
Fiscella, K., Pless, N., Meldrum, S., & Fiscella, P. (2004). Alcohol and opiate withdrawal in US jails. American Journal of Public Health, 94, 1522–1524. https://doi.org/10.2105/ajph.94.9.1522.
Foudray, C. M. A., Kramer, C., Rudes, D. S., Sufrin, C., Burr, E., & Parayil, T. (2021). The compendium of U.S. jails: Creating and conducting research with the first comprehensive contact database of U.S. jails. Health and Justice, 9, 12. https://doi.org/10.1186/s40352-021-00137-7.
Friedmann, P. D., Hoskinson, R., Godon, M., Schwartz, R., Kinlock, T., Knight, K., … MAT Working Group of CJ-DATS (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers and intentions. Substance Abuse, 33(1), 9–18. https://doi.org/10.1080/08897077.2011.611460.
Friedmann, P. D., Taxman, F. S., & Henderson, C. E. (2007). Evidence-based treatment practices for drug-involved adults in the criminal justice system. Journal of Substance Abuse Treatment, 32(3), 267–277. https://doi.org/10.1016/j.jsat.2006.12.020.
Friedmann, P. D., Wilson, D., Knudsen, H. K., Ducharme, L. J., Welsh, W. N., Frisman, L., … Vocci, F. J. (2015). Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. Journal of Substance Abuse Treatment, 50, 50–58. https://doi.org/10.1016/j.jsat.2014.10.001.
Fu, J. J., Zaller, N. D., Yokell, M. A., Bazazi, A. R., & Rich, J. D. (2013). Forced withdrawal from methadone maintenance therapy in criminal justice settings: A critical treatment barrier in the United States. Journal of Substance Abuse Treatment, 44(5), 502–505. https://doi.org/10.1016/j.jsat.2012.10.005.
GAINS Center for Behavioral Health and Justice Transformation, & Substance Abuse and Mental Health Services Administration (2020, October 23). Medication-assisted treatment for opioid use disorder in correctional settings [video]. YouTube. https://www.youtube.com/watch?v=sMTUsJDr4G8
Grella, C. E., Ostlie, E., Scott, C. K., Dennis, M., & Carnevale, J. (2020). A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. International Journal of Drug Policy, 81, 102768. https://doi.org/10.1016/j.drugpo.2020.102768.
Grella, C. E., Ostlie, E., Scott, C. K., Dennis, M. L., Carnevale, J., & Watson, D. P. (2021). A scoping review of factors that influence opioid overdose prevention for justice-involved populations. Substance Abuse Treatment, Prevention, and Policy, 16(1), 1–39. https://doi.org/10.1186/s13011-021-00346-1.
Grella, C. E., Ostlie, E., Watson, D. P., Scott, C. K., Carnevale, J., & Dennis, M. L. (2022). Scoping review of interventions to link individuals to substance use services at discharge from jail. Journal of Substance Abuse Treatment, 108718. https://doi.org/10.1016/j.jsat.2021.108718.
Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E. (2019). Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Network Open, 2(6), e196373. https://doi.org/10.1001/jamanetworkopen.2019.6373.
Hass, A., Viera, A., Doernberg, M., Barbour, R., Tong, G., Grau, L. E., & Heimer, R. (2021). Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014-2018. Drug and Alcohol Dependence, 227, 108937. https://doi.org/10.1016/j.drugalcdep.2021.108937.
Hedegaard, H., Miniño, A. M., & Warner, M. (2020). Drug overdose deaths in the United States, 1999–2019. NCHS data brief, no 394. National Center for Health Statistics https://www.cdc.gov/nchs/data/databriefs/db394-H.pdf.
Hollingsworth, A., Ruhm, C. J., & Simon, K. (2017). Macroeconomic conditions and opioid abuse. Journal of Health Economics, 56, 222–233. https://doi.org/10.1016/j.jhealeco.2017.07.009.
Jalal, H., Buchanich, J. M., Roberts, M. S., Balmert, L. C., Zhang, K., & Burke, D. S. (2018). Changing dynamics of the drug overdose epidemic in the United States, 1979-2016. Science, 361(6409), eaau1184. https://doi.org/10.1126/science.aau1184.
Kertesz, S. G. (2017). Turning the tide or riptide? The changing opioid epidemic. Substance Abuse, 38(1), 3–8. https://doi.org/10.1080/08897077.2016.1261070.
Khatri, U. G., Howell, B. A., & Winkelman, T. N. N. (2021). Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies. Health Affairs, 40(4), 562–570. https://doi.org/10.1377/hlthaff.2020.01251.
Kolak, M., Qinyun Lin, Q., Paykin, S., Menghaney, M., & Li, A. (2021, May 11). GeoDaCenter/opioid-policy-scan: Opioid environment policy scan data warehouse (version v0.1-beta). Zenodo. https://doi.org/10.5281/zenodo.4747876.
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., … O’Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374(13), 1232–1242. https://doi.org/10.1056/NEJMoa1505409.
Macmadu, A., Goedel, W. C., Adams, J. W., Brinkley-Rubinstein, L., Green, T. C., Clarke, J. G., … Marshall, B. D. L. (2020). Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails. Drug and Alcohol Dependence, 28, 107858. https://doi.org/10.1016/j.drugalcdep.2020.107858.
Mattson, C. L., Tanz, L. J., Quinn, K., Kariisa, M., Patel, P., & Davis, N. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morbidity and Mortality Weekly Report, 70(6), 202.
McKenzie, M., Zaller, N., Dickman, S. L., Green, T. C., Parihk, A., Friedmann, P. D., & Rich, J. D. (2012). A randomized trial of methadone initiation prior to release from incarceration. Substance Abuse, 33(1), 19–29. https://doi.org/10.1080/08897077.2011.609446.
Merrall, L. C., Kariminia, A., Binswanger, I. A., Hobbs, M. S., Farrell, M., Marsden, J., … Bird, S. M. (2010). Meta-analysis of drug-related deaths soon after release from prison. Addiction, 105, 1545–1554. https://doi.org/10.1111/j.1360-0443.2010.02990.x.
Mitchell, S. G., Harmon-Darrow, C., Lertch, E., Monico, L. B., Kelly, S. M., Sorensen, J. L., & Schwartz, R. P. (2021). Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services. Journal of Substance Abuse Treatment, 127, 108351. https://doi.org/10.1016/j.jsat.2021.108351.
Monico, L. B., & Mitchell, S. G. (2016). Developing effective interorganizational relationships between community corrections and community treatment providers. Journal of Offender Rehabilitation, 55(7), 484–501. https://doi.org/10.1080/10509674.2016.1218401.
Monnat, S. M. (2018). Factors associated with county-level differences in U.S. drug-related mortality rates. American Journal of Preventive Medicine, 54(5), 611–619. https://doi.org/10.1016/j.amepre.2018.01.040.
Monnat, S. M. (2019). The contributions of socioeconomic and opioid supply factors to U.S. drug mortality rates: Urban-rural and within-rural differences. Journal of Rural Studies, 68, 319–335. https://doi.org/10.1016/j.jrurstud.2018.12.004.
Moore, K. E., Roberts, W., Reid, H. H., Smith, K. M., Oberleitner, L. M., & McKee, S. A. (2019). Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse Treatment, 99, 32–43. https://doi.org/10.1016/j.jsat.2018.12.003.
National Commission on Correctional Health Care (2022). Position statement: Naloxone in correctional facilities for the prevention of opioid overdose deaths. Journal of Correctional Health Care, 28(1), 66–67.
National Governors Association, & American Correctional Association. (2021, February 5). Expanding access to medications for opioid use disorder in corrections and community settings: A roadmap for states to reduce opioid use disorder for people in the justice system. https://www.nga.org/center/publications/expanding-access-medications-oud-corrections-community-settings/
National Sheriffs’ Association, & the National Commission on Correctional Health Care (2018, October). Jail-based medication-assisted treatment: Promising practices, guidelines, and resources for the field. https://www.ncchc.org/filebin/Resources/Jail-Based-MAT-PPG-web.pdf
Pear, K. K., & Monnat, S. M. (2019). Urban-rural variation in the socioeconomic determinants of opioid overdose. Drug and Alcohol Dependence, 195, 66–73. https://doi.org/10.1016/j.drugalcdep.2018.11.024.
Rawson, R., Cousins, S. J., McCann, M., Pearce, R., & Van Donsel, A. (2019). Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system. Journal of Substance Abuse Treatment, 97, 84–90. https://doi.org/10.1016/j.jsat.2018.11.003.
Ray, B., Victor, G., Cason, R., Hamameh, N., Kubiak, S., Zettner, C., … Costello, M. (2022). Developing a cascade of care for opioid use disorder among individuals in jail. Journal of Substance Abuse Treatment, 108751. https://doi.org/10.1016/j.jsat.2022.10875.
Rich, J. D., McKenzie, M., Larney, S., Wong, J. B., Tran, L., Clarke, J., … Zaller, N. (2015). Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomized, open-label trial. Lancet, 386(9991), 350–359. https://doi.org/10.1016/S0140-6736(14)62338-2.
Rigg, K. K., Monnat, S. M., & Chavez, M. N. (2018). Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. International Journal of Drug Policy, 57, 119–129. https://doi.org/10.1016/j.drugpo.2018.04.011.
Scott, C. K., Dennis, M. L., Grella, C. E., Kurz, R., Sumpter, J., Nicholson, L., & Funk, R. R. (2020). A community outreach intervention to link individuals with opioid use disorders to medication-assisted treatment. Journal of Substance Abuse Treatment, 108, 75–81. https://doi.org/10.1016/j.jsat.2019.07.001.
Scott, C. K., Dennis, M. L., Grella, C. E., Mischel, A. F., & Carnevale, J. (2021). The impact of the opioid crisis on U.S. state prison systems. Health & Justice, 9, 17. https://doi.org/10.1186/s40352-021-00143-9.
Scott, C. K., Dennis, M. L., Grella, C. E., & Watson, D. P. (2021). Improving retention across the OUD service cascade upon reentry from jail using recovery management checkups-adaptive (RMC-A) experiment. Journal of Substance Abuse Treatment, 128, 108245. https://doi.org/10.1016/j.jsat.2020.108245.
Sharma, A., O’Grady, K. E., Kelly, S. M., Gryczynski, J., Mitchell, S. G., & Schwartz, R. P. (2016). Pharmacotherapy for opioid dependence in jails and prisons: Research review update and future directions. Substance Abuse and Rehabilitation, 7, 27–40. https://doi.org/10.2147/SAR.S81602.
Simpatico, T. A. (2015). Vermont responds to its opioid crisis. Preventive Medicine, 80, 10–11. https://doi.org/10.1016/j.ypmed.2015.04.002.
Singer, A. J., & Kopak, A. M. (2021). Jail reentry and gaps in substance use disorder treatment in rural communities. Corrections. https://doi.org/10.1080/23774657.2021.1967816.
Smart, R., Grant, S., Gordon, A. J., Pacula, R. L., & Stein, B. D. (2022). Expert panel consensus on state-level policies to improve engagement and retention in treatment for opioid use disorder. JAMA Health Forum, 3(9), e223285. https://doi.org/10.1001/jamahealthforum.2022.3285.
Socías, M. E., Wood, E., Kerr, T., Nolan, S., Hayashi, K., Nosova, E., … Milloya, M.-J. (2018). Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016. Drug and Alcohol Dependence, 189, 90–95. https://doi.org/10.1016/j.drugalcdep.2018.04.026.
Stephenson, J. (2020). COVID-19 pandemic poses challenge for jails and prisons. JAMA Health Forum, 1(4), e200422. https://doi.org/10.1001/jamahealthforum.2020.0422.
Streisel, S. E. (2018). Intent to refer: Exploring bias toward specific medication-assisted treatments by community corrections employees. Substance Use & Misuse, 53(14), 2421–2430. https://doi.org/10.1080/10826084.2018.1482346.
Substance Abuse and Mental Health Services Administration (SAMHSA). (2019). Use of medication-assisted treatment for opioid use disorder in criminal justice settings. HHS Publication No. PEP19-MATUSECJS. National Mental Health and Substance Use Policy Laboratory, SAMHSA. https://store.samhsa.gov/sites/default/files/d7/priv/pep19-matusecjs.pdf
Sufrin, C., Sutherland, L., Beal, L., Terplan, M., Latkin, C., & Clarke, J. G. (2020). Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: Results from a national surveillance study. Addiction, 115, 2057–2065. https://doi.org/10.1111/add.15030.
Taxman, F. S., Young, D. W., Wiersema, B., Rhodes, A., & Mitchell, S. (2007). National Criminal Justice Treatment Practices Survey: Multilevel survey methods and procedures. Journal of Substance Abuse Treatment, 32, P225–P238. https://doi.org/10.1016/j.jsat.2007.01.002.
Taylor, B. G., Lamuda, P. A., Flanagan, E., Watts, E., Pollack, H., & Schneider, J. (2021). Social stigma toward persons with opioid misuse: Results from a nationally representative survey of U.S. adults. Substance Use & Misuse, 56(12), 1752–1764. https://doi.org/10.1080/10826084.2021.1949611.
Victor, G., Zettner, C., Huynh, P., Ray, B., & Sightes, E. (2022). Jail and overdose: Assessing the community impact of incarceration on overdose. Addiction, 117(2), 433–441. https://doi.org/10.1111/add.15640.
Wakeman, S. E., & Rich, J. D. (2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330–333. https://doi.org/10.1080/10826084.2017.1363238.
Weizman, S., Perez, J., Manoff, I., Baney, M., & El-Sabawi T. (2021, July 28). National snapshot: Access to medications for opioid use disorder in U.S. jails and prisons – Litigation, legislation, and policies. O’Neill Institute for National and Global Health Law at Georgetown Law Center. https://oneill.law.georgetown.edu/wp-content/uploads/2021/07/National-Snapshot-Access-to-Medications-for-Opioid-Use-Disorder-in-U.S.-Jails-and-Prisons.pdf
Welsh, W. N., Knudsen, H. K., Knight, K., Ducharme, L., Pankow, J., Urbine, T., & Friedmann, P. D. (2015). Effects of an organizational linkage intervention on inter-organizational service coordination between probation/parole agencies and community treatment providers. Administration and Policy in Mental Health, 43(1), 405–121. https://doi.org/10.1007/s10488-014-0623-8.
Williams, A. R., Nunes, E., Bisaga, A., & Olfson, M. (2018). Developing an opioid use disorder treatment cascade: A review of quality measures. Journal of Substance Abuse Treatment, 91, 57–68. https://doi.org/10.1016/j.jsat.2018.06.001.
Williams, A. R., Nunes, E., & Olfson, M. (2017). To battle the opioid overdose epidemic, deploy the ‘cascade of care’ model. Health Affairs Blog. http://healthaffairs.org/blog/2017/03/13/to-battle-the-opioid-overdose-epidemic-deploy-the-cascade-of-care-model. https://doi.org/10.7916/D8RX9QF3.
Winkelman, T., Chang, V. W., & Binswanger, I. A. (2018). Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Network Open, 1(3), e180558. https://doi.org/10.1001/jamanetworkopen.2018.0558.
Zeng, Z., & Minton, T. D. (2021). Jail inmates in 2019 (NCJ 255608). Department of Justice, Office of Justice Programs, Bureau of Justice Statistics https://bjs.ojp.gov/content/pub/pdf/ji19.pdf.
The authors thank the respondents for completing the survey; the survey coaches; Buce Spencer and Allen Beck for assistance in creating the sample design; Marynia Kolak and Susan Paykin for providing the geocoded data; Dr. Tisha Wiley of NIDA for her helpful input; and Cori Miles, Casey Sarapas, Kate Hart, and Kelli Wright for their assistance in preparing the manuscript.
This article was supported by National Institute on Drug Abuse (NIDA) grant no. U01DA036221 and an accelerator supplement from NIDA on grant no. U01DA036221 to support the Justice Community Opioid Innovation Network (JCOIN). The opinions expressed here are those of the authors and do not represent official positions of the government.
Ethics approval and consent to participate
The study obtained a Certificate of Confidentiality from the National Institutes of Health. The study was conducted under the supervision of Chestnut Health Systems’ Institutional Review Board (IRB) for the Protection of Human Subjects (IRB Research Study No. 1134–0419). Participants gave written consent; their participation in the study was voluntary and they could choose not to answer any question without consequences.
Consent for publication
Not applicable as no individual respondents identified.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1: Supplement A.
Maps of opioid overdose related deaths and rate per 100,000 by County.
Additional file 2: Supplement B.
Instrument Development and Variable Domains for JCOIN Jail Interview.
Additional file 3: Supplement C.
Analysis of Potential Non-Response Bias Among Targeted Jails.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Scott, C.K., Grella, C.E., Dennis, M.L. et al. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.. Health Justice 10, 36 (2022). https://doi.org/10.1186/s40352-022-00197-3
- Opioid use disorder (OUD)
- Opioid overdose
- Best practices
- Medication for opioid use disorder (MOUD)
- Re-entry services
- Training needs